A detailed history of Jpmorgan Chase & CO transactions in Sc Pharmaceuticals Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 12,786 shares of SCPH stock, worth $51,527. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,786
Previous 12,009 6.47%
Holding current value
$51,527
Previous $60,000 8.33%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$3.51 - $5.21 $2,727 - $4,048
777 Added 6.47%
12,786 $55,000
Q1 2024

May 10, 2024

SELL
$4.86 - $6.39 $36,887 - $48,500
-7,590 Reduced 38.73%
12,009 $60,000
Q3 2023

Nov 14, 2023

SELL
$7.0 - $9.82 $19,544 - $27,417
-2,792 Reduced 12.47%
19,599 $139,000
Q2 2023

Aug 11, 2023

BUY
$8.94 - $11.74 $31,710 - $41,641
3,547 Added 18.82%
22,391 $228,000
Q1 2023

May 11, 2023

SELL
$5.59 - $9.47 $188,595 - $319,498
-33,738 Reduced 64.16%
18,844 $170,000
Q4 2022

Feb 13, 2023

BUY
$4.02 - $7.53 $211,379 - $395,942
52,582 New
52,582 $377,000
Q1 2022

May 11, 2022

SELL
$3.9 - $6.11 $54 - $85
-14 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$3.88 - $6.9 $54 - $96
14 New
14 $0

Others Institutions Holding SCPH

About scPharmaceuticals Inc.


  • Ticker SCPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,402,100
  • Market Cap $110M
  • Description
  • scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product p...
More about SCPH
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.